A 2016 systematic review of 5 studies using Bacopa monnieri in child and adolescent participants found that supplementation may improve behavioral and cognitive outcomes.[1] However, two of the studies had no control group. More robust study designs are needed to determine the efficacy of Bacopa in children and adolescents. There was also a 2022 randomized controlled trial investigating the efficacy of Bacopa monnieri’s ability to reduce attention and hyperactivity in male children ages 6 to 14.[2] No differences were noted for behavioral outcomes, but there were some improvements in the Bacopa group for certain cognitive outcomes, such as cognitive flexibility and processing speed. It is essential for parents to discuss supplements with a clinician before administering them to a child, as children can have different reactions to supplements than adults.
Could Bacopa monnieri benefit children?
Written by:
Fact-checked
by:
•Last Updated: May 16, 2025
A 2016 systematic review indicated that Bacopa monnieri may improve behavioral and cognitive outcomes in children, though more rigorous studies are needed. A 2022 trial showed some cognitive improvements in children aged 6 to 14, but no behavioral differences were noted, which highlights the importance of consulting a clinician before giving supplements to children.